HFB200301 + tislelizumab

HFB200301 + tislelizumab is an investigational combination immunotherapy for advanced solid tumors. HFB200301 is a first-in-class agonistic anti-TNFR2 monoclonal antibody that selectively binds to TNFR2 (tumor necrosis factor receptor 2) and activates CD4+ T cells, CD8+ T cells, and NK cells, inducing antitumor immune responses. Tislelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody immune checkpoint inhibitor designed to minimize Fc-gamma receptor binding, thereby enhancing its antitumor effect by promoting effector T cell activity. The combination is being evaluated in early-phase clinical trials for safety and preliminary efficacy, with rationale based on potential synergistic activation and expansion of cytotoxic T cells to enhance antitumor activity, especially in indications where previous treatments have failed[3][5][7].

Brand names

Tevimbra

Other names

HFB-200301HFB200301HFB 200301HFB200301 + Tevimbra